Company news

Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A (SSE:600671) news

Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A news releases on 6ix. Latest, Sep 22, 2026: "Hangzhou Tianmushan Pharmaceutical Enterprise Co.…

Hangzhou Tianmushan Pharmaceutical Enterprise Co Ltd Class A (SSE:600671) news

Press releases & updates

"Hangzhou Tianmushan Pharmaceutical Enterprise Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing

"Hangzhou Tianmushan Pharmaceutical Enterprise Co., Ltd."Announcement on Progress in Providing Guarantee for Controlled Subsidiary

"Hangzhou Tianmushan Pharmaceutical Enterprise Co., Ltd."Announcement on Provision for Credit Impairment and Asset Impairment for the First Half of 2026

"Hangzhou Tianmushan Pharmaceutical Enterprise Co., Ltd."Announcement on the Public Solicitation of Transferees for the Controlling Shareholder's Proposed Transfer of Certain Shares of the Company through Public Solicitation and Agreement

"Hangzhou Tianmushan Pharmaceutical Enterprise Co., Ltd."Indicative Announcement on Proposed Transfer of Part of Company's Shares by Controlling Shareholder through Public Solicitation and Possible Change in Control

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

Announcement on Reply to Letter of Supervision and Inquiry of 2025 Annual Report

Announcement on Resolutions of the 20th Meeting of the 12th Board of Directors

Announcement on Listing and Circulation of Shares Subject to Lock-Up from Shareholding Reform

Announcement on Convening Performance Briefing for 2025 and Q1 2026

Announcement on Resolutions of the 2025 Annual General Meeting

Report for Q1 2026

Announcement on Purchasing Liability Insurance for Directors and Senior Management Members

Announcement on Progress in Guarantees Provided for the Company's and Its Subsidiary's Application for Comprehensive Credit Line from Banks and Other Financial Institutions in 2025

Announcement on Abnormal Fluctuations in Stock Trading

Announcement on Resolutions of the 4th Extraordinary General Meeting in 2025

Announcement on Obtaining Notice of Approval for Re-Registration of Drug by Wholly-owned Subsidiary

Announcement on Expiration of the Plan for Issuance of Stocks to Specific Objects

Announcement on Progress in Guarantees Provided to Subsidiaries and Guarantees Provided by Subsidiaries

Announcement on Convening the Q3 2025 Performance Briefing

Announcement on the Termination of the Original Lease Contract of the Subsidiary’s Property, Signing of a New Lease Contract, and the Related Party Transaction

Announcement on Renewal of Drug Production License

Announcement on Reply to Letter from Shanghai Stock Exchange on Information Disclosure and Supervision

Announcement on Outline of the 2025 Semi-annual Performance Briefing

Announcement on Convening the 2025 Semi-annual Performance Briefing

Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025

Announcement on Resolutions of the 15th Meeting of the 12th Board of Directors

2025 Semi-annual Report

Announcement on Obtaining Notice of Approval for Re-Registration of Drug by the Subsidiary

Announcement on Expected Increase in Semi-annual Performance for 2025

Announcement on Outline of the 2024 Annual Performance Briefing

Announcement on Convening the 2024 Annual Performance Briefing

Announcement on Reply to Letter from Shanghai Stock Exchange on Information Supervision

Announcement on Resolution of the 2nd Extraordinary General Meeting in 2025

Report for Q1 2025

Announcement on Progress in Application for the Removal of Other Risk Warnings for Corporate Stocks

Announcement on Resolution of the 2024 Annual General Meeting

Announcement on Resolutions of the 12th Meeting of the 12th Board of Directors

Announcement on Not Profit Distribution for 2024

Announcement on Resolution of the 1st Extraordinary General Meeting in 2025

Announcement on the Progress of the Company's Renewal of Loans for Subsidiaries and Subsidiaries Providing Guarantees for Loans to Other Subsidiaries

Notice on Convening the 1st Extraordinary General Meeting in 2025

Announcement on Completion of Shareholding Reduction Plan for Shareholders with Over 5% Shares

Indicative Announcement on Progress in Share Increase of Shareholder Holding More Than 5% Shares and Equity Change Reaching 1%

Announcement on the Progress of Wholly-owned Subsidiary Huangshan Tianmu Pharmaceutical Co., Ltd in Implementing the Production Capacity Improvement and Technical Transformation Project

Announcement on Expected Gains in Annual Performance for 2024

Announcement on Reply to the Information Disclosure Regulatory Letter on the Report for Q3 2024

Announcement on Resolution of the 6th Extraordinary General Meeting in 2024

Announcement on Receiving Letter of Regulation from Shanghai Stock Exchange on Information Disclosure of the Company's Report for Q3 2024

Announcement on Progress in Shareholding Increase Plan for Shareholders with Over 5% Shares and Over Half of the Plan Period